lactobacillus sakei
Cell therapyexperimental
Latilactobacillus sakei is the type species of the genus Latilactobacillus that was previously classified in the genus Lactobacillus. It is homofermentative; hexoses are metabolized via glycolysis to lactic acid as main metabolite; pentoses are fermented via the phosphoketolase pathway to lactic and acetic acid. — Wikipedia
Clinical trial activity
3 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
1
Earliest trial started Jan 1, 2007 (NCT00893230)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 3 Sponsor(trial)
Indications
Approved for
Mechanism of action
- microbiotaTissue restoration
microbiota tissue restoration
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaLatilactobacillus sakei ↗
- WikipediaLactobacillus sakei ↗
Also known as
- probiotic l sakei kctc 10755bp
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05427695 | Phase 4 | Sep 1, 2022 | Cures Within Reach, University of Illinois at Chicago |
| NCT03248414 | N/A | Aug 10, 2016 | Seoul National University |
| NCT00893230 | Phase 3 | Jan 1, 2007 | Chungbuk National University, Gachon University, Korea Research Institute of Bioscience & Biotechnology, Yeungnam University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chungbuk National University | Academic/Hospital | 1 | 1 | 1 | 2007 |
| Cures Within Reach | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Gachon University | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Korea Research Institute of Bioscience & Biotechnology | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Seoul National University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| University of Illinois at Chicago | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Yeungnam University | Academic/Hospital | 1 | 0 | 1 | 2007 |
7 organizations
Page 1 / 1